2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-177624
    Cupabimod 297774-48-2
    Cupabimod is a decoy oligodeoxynucleotide for transcription factor NF-κB.
    Cupabimod
  • HY-177701
    MMP-9-IN-13 3085676-77-0 98.07%
    MMP-9-IN-13 (Example 1) is a selective inhibitor of human MMP9 with an IC50 value of 0.02 nM. MMP-9-IN-13 can be used in the research of ocular surface.
    MMP-9-IN-13
  • HY-177963
    NV914 2341941-41-9 98.98%
    NV914 is an inhibitor of FTSJ1 (tryptophan tRNA-specific 2'-O-methyltransferase) that inhibits the methyltransferase activity of FTSJ1, induces translational readthrough of premature termination codons, and enables genes carrying nonsense mutations to synthesize full-length proteins. NV914 belongs to translational readthrough-inducing compounds (TRIDs). NV914 exhibits translational readthrough activity against nonsense mutations in in vitro systems, does not induce readthrough of natural termination codons, and restores CFTR protein expression. NV914 shows favorable acute oral tolerance in mice, with low health risks and good safety profiles. NV914 is applicable to research related to cystic fibrosis and Shwachman-Diamond syndrome.
    NV914
  • HY-178037
    TLR9 antagonist 1 3105410-45-2 98%
    TLR9 antagonist 1 is a selective hTLR9 antagonist with an IC50 of 0.1 nM against hTLR9. TLR9 antagonist 1 exhibits favorable pharmacokinetic and pharmacodynamic properties. TLR9 antagonist 1 can be used in the research of systemic lupus erythematosus.
    TLR9 antagonist 1
  • HY-178041
    BRD4-BD1/2-IN-3 3106588-54-6 99.52%
    BRD4-BD1/2-IN-3 (Compound B6) is a selective BRD4 BD2 inhibitor with an IC50 of 0.41  nM for BRD4 BD2 over BRD4 BD1. BRD4-BD1/2-IN-3 significantly inhibits the LPS (HY-D1056)-induced expression of IL-6. BRD4-BD1/2-IN-3 shows anti-inflammatory activities by modulating the TNF and NF-κB signaling pathway. BRD4-BD1/2-IN-3 can be used for inflammatory diseases research.
    BRD4-BD1/2-IN-3
  • HY-178049
    UM-259
    UM-259 is a STING inhibitor, with an EC50 of 1.50 μM in THP1-Dual cells expressing wild-type STING. UM-259 blocks STING oligomerization and inhibits diABZI-induced phosphorylation of TBK1 and IRF3, thereby suppressing the transcription of IFNβ and IL6 and reducing IFNβ secretion. UM-259 can be used for the study of STING-dependent inflammatory and neurological diseases.
    UM-259
  • HY-178227
    KY19334 2319609-67-9 98%
    KY19334 is a CXXC5-DVL inhibitor. KY19334 can activate the Wnt/β-catenin pathway by inhibiting CXXC5-Dvl interaction. KY19334 can inhibit cancer cells proliferation, migration, invasion and transformation by inhibiting CDK1. KY19334 can accelerate wound healing and exert regenerative effects. KY19334 can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as cutaneous squamous cell carcinoma and diabetes.
    KY19334
  • HY-178239
    DX-8951 Hydroxy-acid 276680-63-8 98%
    DX-8951 Hydroxy-acid is a prodrug of phosphoramide. ProAX can effectively increase intracellular ATP levels. DX-8951 Hydroxy-acid activates the AMPK signaling pathway by increasing the AMP/ATP ratio. DX-8951 Hydroxy-acid can enhance mitochondrial function and antioxidant capacity while reducing reactive oxygen species (ROS) levels. DX-8951 Hydroxy-acid has shown significant anti-aging and longevity effects in both human fibroblast and nematode models.
    DX-8951 Hydroxy-acid
  • HY-178821
    ROCK2-IN-12 3086603-12-2 98.02%
    ROCK2-IN-12 (Compound A25) is a selective ROCK2 inhibitor with an IC50 of 7.0  nM for ROCK2 over ROCK1. ROCK2-IN-12 has potent antifibrotic effects via the TGF-β/Smad and ROCK2/STAT3 signaling pathways. ROCK2-IN-12 significantly reduces collagen deposition and reverses fibrotic progression in Bleomycin (HY-108345)-induced pulmonary fibrosis (PF) mouse models. ROCK2-IN-12 can be used for lung diseases like pulmonary fibrosis research.
    ROCK2-IN-12
  • HY-179371
    LIQ1 2606032-80-6
    LIQ1, a flavonoid derivative, is a potent Pyruvate kinase M2 (PKM2) allosteric inhibitor (IC50 = 0.39 μM; Kd = 4.5 μM) targeting Arg43 within the polyarginine pocket. LIQ1 exhibits efficacy in a mouse model of LPS (HY-D1056)-induced endotoxemia, preventing the nuclear translocation of PKM2 and inhibiting its binding to HIF-1α, thereby suppressing IL-1β transcription. LIQ1 can be used for the research of endotoxemia[1].
    LIQ1
  • HY-179421
    PROTAC HDAC6 degrader 7 98%
    PROTAC HDAC6 degrader 7 is an orally active, highly efficient, and selective PROTAC degrader targeting histone deacetylase 6 (HDAC6) (IC50 = 118 nM). PROTAC HDAC6 degrader 7 can eliminate both the catalytic and zinc-finger ubiquitin-binding domain. PROTAC HDAC6 degrader 7 inhibits NLRP3 inflammasome assembly and activation, as well as blocks NF-κB signaling, thereby reducing the transcription and release of key inflammatory factors. PROTAC HDAC6 degrader 7 can reduce the mRNA levels of NLRP3, pro-IL-1β, TNF-α, and IL-6. PROTAC HDAC6 degrader 7 can be used for the study of inflammatory bowel disease (IBD).
    PROTAC HDAC6 degrader 7
  • HY-179474
    TSI-13-57 2257427-45-3 98.73%
    TSI-13-57 is a pan-TLR inhibitor (IC50: 2.7 μM, 6.03 μM, 7.37 μM, 6.38 μM for TLR9, TLR7, TLR2, TLR4, respectively). TSI-13-57 inhibits homodimerization of the TIR domains of MyD88. TSI-13-57 reduces systemic inflammatory responses in LPS-induced mice.
    TSI-13-57
  • HY-179537
    CKBA 1786406-66-3 98%
    CKBA, a derivative of AKBA (HY-N0892) is an inhibitor of acetyl-CoA carboxylase 1 (ACC1), with an IC50 of 5.02 μM. CKBA inhibits the differentiation of Th17 cells and has IC50 values of 3.28 μM for mouse cells and 3.61 μM for human cells. CKBA ointment significantly alleviates psoriasis-like inflammation in mice. CKBA can be used for the study of psoriasis.
    CKBA
  • HY-180559
    nAChR antagonist 2
    nAChR antagonist 2 is a selective nAChR antagonist. nAChR antagonist 2 inhibits nAChR subtype including hα9α10, hα9, and hα7 with IC50 values of 16.0 nM, 26.2 nM, and 336.3 nM, respectively, in Xenopus oocytes. nAChR antagonist 2 suppresses ATP-induced IL-1β release at nanomolar concentrations. nAChR antagonist 2 can be used for nonopioid analgesics and immunomodulators research.
    nAChR antagonist 2
  • HY-180888
    Lck-IN-5 1356734-45-6 98.09%
    Lck-IN-5 (example C10) is a potent and selective lymphocyte-specific protein tyrosine kinase (LCK) inhibitor. Lck-IN-5 selectively disrupts the interaction between the SH3 domain of LCK and the RK motif of CD3ε, thereby impairing LCK recruitment to the TCR. Lck-IN-5 modulates the activity of CD3ε-containing CAR and TRuC T cells, attenuating cytokine production and promoting a central-memory-like phenotype associated with enhanced persistence. Lck-IN-5 can be used for autoimmune diseases and graft-versus-host disease research.
    Lck-IN-5
  • HY-181418
    HY-072808 2230498-45-8 98.75%
    HY-072808 is a cyclic nucleotide phosphodiesterase-4B (PDE4B) inhibitor.HY-072808 modulates cyclic nucleotide signaling via selective inhibition of the PDE4B subtype.HY-072808 can be used for the research of atopic dermatitis.
    HY-072808
  • HY-181526
    Sim-9 3099101-40-0
    Sim-9 is a covalent allosteric inhibitor of interferon regulatory factor 3 (IRF3). Sim-9 binds covalently to the Cys222 residue of IRF3, induces its conformational change, blocks its interactions with TRIF, MAVS and STING, and inhibits IRF3 homodimerization and type I interferon response. Sim-9 exhibits significant anti-inflammatory, organ-protective and survival benefits in mouse models of sepsis and acute pancreatitis. Sim-9 can be used for research related to inflammatory diseases.
    Sim-9
  • HY-182097
    DSPE-PEG1000-GNYTCEVTELTREGETIIELK 98%
    DSPE-PEG1000-GNYTCEVTELTREGETIIELK is a PEG compound which composed of DSPE and a peptide mimicking the function of CD47 (GNYTCEVTELTREGETIIELK). Modifying the surface of LNPs with GNYTCEVTELTREGETIIELK significantly reduced the recognition and clearance of LNPs by the mononuclear phagocytic system (MPS), and decreased their accumulation in non-target tissues such as the liver and spleen. DSPE-PEG1000-GNYTCEVTELTREGETIIELK can be used for drug delivery.
    DSPE-PEG1000-GNYTCEVTELTREGETIIELK
  • HY-18342S
    Diflunisal-d3 1286107-99-0 99.71%
    Diflunisal-d3 is the deuterium labeled Diflunisal. Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients. The mechanism of action of diflunisal is as a Cyclooxygenase (COX) Inhibitor.
    Diflunisal-d3
  • HY-185350
    α4β7 Integrin-IN-2 2640360-68-3 98%
    α4β7 Integrin-IN-2 is an inhibitor of human α4β7 integrin with an IC50 <5 nM. α4β7 Integrin-IN-2 modulates α4β7 integrin-mediated biological pathways. α4β7 Integrin-IN-2 can be used for the research of inflammatory dieases.
    α4β7 Integrin-IN-2
Cat. No. Product Name / Synonyms Application Reactivity